• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022 年越南一家三级医院胃肠道癌症患者的质量调整生命年支付意愿。

Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.

机构信息

Faculty of Public Health, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.

Department of Epidemiology, Hanoi University of Public Health, Hanoi, Vietnam.

出版信息

Asian Pac J Cancer Prev. 2024 May 1;25(5):1725-1735. doi: 10.31557/APJCP.2024.25.5.1725.

DOI:10.31557/APJCP.2024.25.5.1725
PMID:38809645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318811/
Abstract

BACKGROUND

Gastrointestinal (GI) cancer burden in Asia is increasing, and Vietnam is no exception. Assessing the affordability of achieving a quality-adjusted life year (QALY) in gastrointestinal cancer patients Vietnam, as well as identifying predictors of willingness to pay (WTP) per QALY, is crucial to decision-making around medical intervention prioritization and performing medical technology assessments for these cancers.

OBJECTIVES

Our study aimed to estimate WTP/QALY gained and associated factors among patients diagnosed with GI cancer at a tertiary hospital in Hue, Vietnam.

METHODS

A cross-sectional descriptive study, using contingent valuation methodology was conducted among 231 patients at tertiary hospital in 2022. A double limited dichotomous choice and the EQ-5D-5L were utilised to estimate WTP and QALY, respectively. Quantile regression was applied to determine predictors of WTP/QALY.

RESULTS

The mean and median maximum WTP/QALY gained among GI patients was $15,165.6 (42,239.6) and $4,365.6 (IQR: 1,586.5-14,552.0), respectively, which was equal to 3.68 times the 2022 gross domestic product (GDP) per capita in Vietnam.  Additionally, cancer severity was found to have a significant impact  on WTP per QALY gained, with a higher amount identified among patients with earlier stages of GI cancer. Furthermore, living in an urban dwelling and patients' treatment modalities were significantly associated with WTP/QALY.

CONCLUSION

Evidence from our study can be used to inform how decision-makers in Vietnam to determine the cost-effectiveness of GI cancer interventions.

摘要

背景

亚洲地区的胃肠道(GI)癌症负担正在增加,越南也不例外。评估越南胃肠道癌症患者实现质量调整生命年(QALY)的负担能力,以及确定每 QALY 支付意愿(WTP)的预测因素,对于医疗干预措施的优先级决策以及对这些癌症进行医疗技术评估至关重要。

目的

我们的研究旨在估计在越南 Hue 的一家三级医院诊断为胃肠道癌症的患者的每 QALY 支付意愿(WTP)和相关因素。

方法

2022 年在一家三级医院进行了一项横断面描述性研究,使用了条件价值评估方法。利用双限制二项选择和 EQ-5D-5L 分别估计 WTP 和 QALY。应用分位数回归来确定 WTP/QALY 的预测因素。

结果

胃肠道癌症患者的平均和中位数最大 WTP/QALY 分别为 15165.6 美元(42239.6 越南盾)和 4365.6 美元(IQR:1586.5-14552.0 越南盾),这相当于 2022 年越南人均国内生产总值(GDP)的 3.68 倍。此外,癌症严重程度对每 QALY 获得的 WTP 有显著影响,GI 癌症早期阶段的患者支付意愿更高。此外,居住在城市地区和患者的治疗方式与 WTP/QALY 显著相关。

结论

我们研究的证据可以为越南决策者确定胃肠道癌症干预措施的成本效益提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4c/11318811/184ceb98b3ef/APJCP-25-1725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4c/11318811/184ceb98b3ef/APJCP-25-1725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4c/11318811/184ceb98b3ef/APJCP-25-1725-g001.jpg

相似文献

1
Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.2022 年越南一家三级医院胃肠道癌症患者的质量调整生命年支付意愿。
Asian Pac J Cancer Prev. 2024 May 1;25(5):1725-1735. doi: 10.31557/APJCP.2024.25.5.1725.
2
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
3
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.泰国为挽救生命的治疗所支付的每质量调整生命年的意愿。
BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
4
Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.评估治愈每质量调整生命年的支付意愿:一种基于情景调查的条件价值评估方法。
Medicine (Baltimore). 2018 Sep;97(38):e12453. doi: 10.1097/MD.0000000000012453.
5
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.肿瘤学中治愈性疗法价值的评估:一项在中国的支付意愿研究。
Cost Eff Resour Alloc. 2023 Jun 5;21(1):37. doi: 10.1186/s12962-023-00442-y.
6
Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.支付意愿以获得额外一年质量调整生命年:来自中国的一项基于人群的调查。
Appl Health Econ Health Policy. 2022 Nov;20(6):893-904. doi: 10.1007/s40258-022-00750-z. Epub 2022 Aug 8.
7
A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.对一般希腊人群体进行质量调整生命年货币价值的条件价值评估研究。
Value Health Reg Issues. 2020 Sep;22:36-43. doi: 10.1016/j.vhri.2020.03.002. Epub 2020 Jul 27.
8
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.一项关于估计伊朗西部挽救生命治疗的成本效益阈值的探索性研究。
Cost Eff Resour Alloc. 2020 Oct 23;18:47. doi: 10.1186/s12962-020-00241-9. eCollection 2020.
9
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.
10
Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet Nam, 2018.2018年越南晚期非小细胞肺癌患者对质量调整生命年的支付意愿。
Medicine (Baltimore). 2020 Feb;99(9):e19379. doi: 10.1097/MD.0000000000019379.

本文引用的文献

1
A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.一项关于直接 elicitation 需求方成本效益阈值的系统评价:对低收入和中等收入国家的启示。
PLoS One. 2024 Feb 8;19(2):e0297450. doi: 10.1371/journal.pone.0297450. eCollection 2024.
2
Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?真实世界成本效益分析:结果中有多少不确定性?
Curr Oncol. 2023 Apr 7;30(4):4078-4093. doi: 10.3390/curroncol30040310.
3
Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review.
癌症预防、筛查、诊断和治疗的支付意愿:系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2023 Mar;23(3):281-295. doi: 10.1080/14737167.2023.2167713. Epub 2023 Jan 24.
4
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.多癌种早期检测基因组血液检测的潜在基于价值的价格,以补充美国当前的单一癌症筛查。
Pharmacoeconomics. 2022 Nov;40(11):1107-1117. doi: 10.1007/s40273-022-01181-3. Epub 2022 Aug 30.
5
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.
6
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review.2015 年至 2020 年期间,用于评估中低收入国家卫生干预措施的成本效益阈值:综述。
Value Health. 2022 Mar;25(3):385-389. doi: 10.1016/j.jval.2021.08.014. Epub 2021 Oct 29.
7
Trends in colorectal cancer incidence in Ho Chi Minh City, Vietnam (1996-2015): Joinpoint regression and age-period-cohort analyses.越南胡志明市结直肠癌发病率趋势(1996-2015 年):Joinpoint 回归和年龄-时期-队列分析。
Cancer Epidemiol. 2022 Apr;77:102113. doi: 10.1016/j.canep.2022.102113. Epub 2022 Jan 22.
8
Willingness-to-pay for cancer treatment and outcome: a systematic review.癌症治疗和结局的支付意愿:系统综述。
Eur J Health Econ. 2022 Aug;23(6):1037-1057. doi: 10.1007/s10198-021-01407-9. Epub 2021 Dec 2.
9
The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine.成本效益分析在精准医学时代以患者为中心的癌症护理中的作用。
Cancers (Basel). 2021 Aug 25;13(17):4272. doi: 10.3390/cancers13174272.
10
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.患者疾病严重程度和年龄与健康相关生活质量收益相关的支付意愿。
Value Health. 2021 Aug;24(8):1182-1192. doi: 10.1016/j.jval.2021.01.012. Epub 2021 Apr 29.